11 February 2016 - Sandoz announced today that the EMA has accepted their Marketing Authorization Application for its biosimilar to Amgen's EU-licensed Neulasta (pegfilgrastim) - a long-acting recombinant human granulocyte colony-stimulating factor. Sandoz is seeking approval for the same indication as the reference product.

For more details, go to: http://www.sandoz.com/media_center/press_releases_news/global_news/2016-02-11_ema-acceptance-pegfilgrastim.shtml